News
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
Stories and articles featuring PCI, our partners, and Penn-affiliated spinout companies
EpiVario is developing neuroepigenetic modulators to treat memory-related addiction and psychiatric disorders.
The drug relies on licensed foundational gene therapy technology created in the laboratory of Dr. James Wilson, MD, PhD.
Interius intends to begin patient enrollment for the trial in the fourth quarter of 2024.
The collaboration combines Ascidian's RNA exon editing technology with Roche's expertise in CNS delivery to create novel treatments for hard-to-treat neurological conditions.
The company reported positive results in the first two patients who received its new CAR T therapy, CABA-201, which aims to treat the autoimmune diseases lupus and myositis.
The Greater Philadelphia Chamber of Commerce published a comprehensive snapshot of the region’s cell and gene therapy sector.
Startup Genome ranked Philadelphia as 25th within the Global Startup Ecosystem in 2024. The report highlights Penn’s role in supporting the ecosystem through various activities.
Philadelphia's venture capital market posted robust results last quarter, with nearly $643 million raised across 100 deals.
PCI and its successful efforts to support Penn's research and innovation over the past decade were highlighted in the Summer issue of the Penn Gazette.
Penn ranked #13 in 2023, compared to #15 in 2022.